James Dyett
San Francisco, California, United States
17K followers
500+ connections
View mutual connections with James
James can introduce you to 10+ people at Thrive Capital
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View mutual connections with James
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Activity
17K followers
-
James Dyett posted thisToday, I’m closing my chapter at OpenAI after three very meaningful years. I leave with deep gratitude for the opportunity to help scale the GTM organization. The timing feels right. I’m drawn back to the early stages of company building, and OpenAI is in a strong place—with GPT-5.5, Codex, and Denise Holland Dresser's inspired leadership. I’m joining Thrive Capital as an Operator in Residence. I’ve been fortunate to work at Thrive-backed companies over the past decade—first Stripe, then OpenAI—and have experienced firsthand their commitment to their companies. I’m excited to pay that forward to founders across the portfolio and stay close to building. To my OpenAI teammates: thank you. Special gratitude to Brad Lightcap for taking a bet on me. And to the Thrive team—I can’t wait to get started.
-
James Dyett shared thisExcited to see Rowspace out of stealth! Congrats Michael Manapat and Yibo LingJames Dyett shared thisI've gotten to spend time over the past year with some of the most forward-thinking investors in the world, learning where AI is meeting their needs and where it isn’t. All of these firms know they need to drive AI transformation on a fast timeline. But, as one put it bluntly: “All these AI tools are only as good as the data you feed them, and ours is a mess.” This may be true, but their data also represents decades spent building proprietary knowledge that codifies how they think, operate, and win. It just happens to be scattered and fragmented across many systems. The real challenge is scaling this edge to make faster, sharper decisions. There's no quick-win alpha. That's why we built Rowspace—launching today with $50M from Sequoia Capital, Emergence Capital, Stripe, Conviction, Basis Set, Twine Ventures, and many others. What we do: -Map firm data comprehensively—memos, decks, models, ledgers, positions, etc. from systems like Salesforce, DealCloud, Box, Egnyte, SharePoint, Everest, Dynamo, Snowflake, PowerBI, and more. We do this in our customers’ environments for maximum data security. -Model how they actually work—reconciling conflicts, deciding what to trust, what to prioritize, what to ignore. We extract meaning and make it available on demand. (It's one thing to recall an answer from a database. It's another to know which addbacks apply to an EBITDA calculation based on a specific credit covenant.) -Push that intelligence into the tools where decisions happen—chat, real-time dashboards, Excel, Teams, wherever you already work—with full traceability down to the calculation. We're already working with some of the most storied firms in the industry: a global growth pioneer with 50 years of history, a crossover fund invested in the most notable tech IPOs of the last decade, and one of the leading credit originators in the world. They chose Rowspace for the depth, nuance, and specificity we’re able to deliver. Try Rowspace if your firm wants to accelerate with AI in ways you can trust. Or come build with us if you want to build at this level of depth for customers shaping our economy.
-
James Dyett shared thisCongrats to Ankur Goyal and Braintrust! You all quickly realized that enterprises need evals to ship great AI products and have executed relentlessly over the past few years.James Dyett shared thisWe sent a note to our customers letting them know that Braintrust has raised a new round of funding and thanking them for their support. While the money is exciting, our focus hasn't changed: we're building Braintrust to help our customers ship quality AI products. In 2026, AI is moving to production but teams have never had less conviction about what will fail next. Our customers are building AI products that serve millions and simply need to work. If Braintrust makes their lives easier and their products better, I know we are doing our job. Thank you to ICONIQ for leading our Series B, and to Andreessen Horowitz, Greylock Partners, basecase capital, and Elad Gil for doubling down. Thank you to the Braintrust team for all the incredible work you've done over the past year. And thank you to our customers, who have made this growth possible. Hear directly from Notion, Vercel, BILL, and Navan about why they use Braintrust to support their AI in production.
-
James Dyett shared thisI had a chance to work closely with Duco van Lanschot and David Schreiber while at Stripe and they are not just brilliant founders but wonderful people and friends. [side note - Duco van Lanschot performed the most hilarious piano roast of the Stripe exec team to a few thousand people and they're bringing the same joy, boldness, and creativity to business identity.] Keep an eye on Duna and congrats to the entire team on their €30m Series A from CapitalG. https://lnkd.in/giJe5bFcStripe alumni raise €30M Series A for Duna, backed by Stripe and Adyen execs | TechCrunchStripe alumni raise €30M Series A for Duna, backed by Stripe and Adyen execs | TechCrunch
-
James Dyett reposted thisJames Dyett reposted thisI am hiring Account Directors for my Digital Natives team at OpenAI in New York. We are looking for 14+ years of sales experience and a track record of top performance in a fast-moving environment (see our recent ships of GPT Image 1.5, GPT-5.2, and GPT-5.2-Codex) We have an amazing group of customer-first, technical, curious sellers who are doing meaningful work each day shepherding this new technology to our customers that you'd get to work alongside of. If you are interested, please send me your resume or a short note via LinkedIn and I'll make sure to take the time to go through these. You can also apply directly here (https://lnkd.in/e2ZAGTTQ) https://lnkd.in/e7QNZ7m5 https://lnkd.in/ei9_JNiQ https://lnkd.in/ert82fZk
-
James Dyett shared thisIt's worth checking out the voice AI solution in the T-Life app. Impressive execution by their team. Thanks for the partnership Jeff Simon Grant R Julianne Roberson Mike Katz Srini GopalanJames Dyett shared thisT-Mobile customers can get answers to pricing, promotions, eligibility and plan questions the moment they need them using real-time voice AI in the T-Life app, helping make upgrades easier. We built this experience in close collaboration with OpenAI, and thousands of customers have already used it with strong results. Simple. Supportive. Built for customers.
-
James Dyett shared thisOpenAI and Disney! We're excited to work with Disney as a customer, partner, and investor. Thanks to Jamie Voris Justin Warbrooke David Min and many others who worked hard over many years to reach this agreement.
-
James Dyett shared thisIt's hard to imagine a better use of AI than discovering new medicines which makes this result from Chai Discovery something that should give us all optimism. Congrats Jack Dent and team!James Dyett shared thisToday, we’re releasing new data showing that Chai-2 can design antibodies against challenging targets with atomic precision. In June, we introduced Chai-2, showing it could design antibodies zero-shot in a 24-well plate. In this new data, we show that Chai-2 can: 💡Design full-length mAbs, with >86% of designs showing developability characteristics on par with approved therapeutics, while maintaining the high hit rates we previously reported. 🔬Achieve atomic-level precision on epitope targeting, with Cryo-EM structures matching model designs across five antibody-antigen complexes 🏁 Generate binders and functional agonists against a panel of six GPCRs, which are notoriously hard-to-drug targets. Testing just <75 designs for each, we obtain a binder in every case (median hit rate: 21%). We discover functional agonists to two distinct GPCR targets. 🔎 Design antibodies for peptide-MHC that discriminate single-residue mutations, including binders specific to KRAS G12V over G12D and wild-type peptides These results provide a glimpse into a new paradigm, where drug designs are conceived on the computer and predictive models approach the precision of the wet lab. Thank you to many partners for making this possible: Oracle, Mithril, Amazon Web Services (AWS), NVIDIA, Modal for compute; Sino Biological, GenScript for conducting many wet-lab experiments in the paper.
-
James Dyett shared thisOpenAI and Target are expanding our work together to bring practical AI into everyday retail. Target is bringing ChatGPT Enterprise to 18,000 employees and building on our platform to power experiences like Agent Assist, Store Companion, and a new Target app inside ChatGPT for personalized shopping. It’s another example of how large retailers are starting to run key workflows on AI to improve operations and serve customers better.
-
James Dyett liked thisJames Dyett liked thisAll I knew about Mishti Sharma when I hired her in 2023 was that she was the best writer I knew. Clay was 10 people back then. She had no interest in joining, and we didn't really NEED a full-time content person. But hiring people who are world-class at something — and putting them in an environment where they can lean into their natural spikes — has never let me down. That has invariably been how we've cultivated our uniqueness, and I've been happy to get creative about roles, pay, and titles to make it happen. Today First Round Capital published an incredible 5,000 word article by Mishti — now our Head of Narratives — on what happened when she decided to take the plunge and join Clay: how we built a role around her strengths as a storyteller, how that work shaped our brand, and how we scaled past $100M ARR in the process. And as to be expected, it's the most intimate and moving portrait ever written about Clay. Near the end, she captures what has become our North Star for our people: "Looking back, I think what made all of this possible was simple: Clay created the conditions where I felt safe enough to be myself. When I finally relaxed, trusted my team, and did the work that was most mine, the output was something that no other company could have replicated." This is the sense of psychological safety that we're dedicated to creating, and that I know will make us the best employer in the world. Every day, we ask people to do the most creative work of their careers, and we do it by seeing who they actually are — far beyond just a title or a resume. Read the full piece for the whole story... and an inside look at the many ways I've grown since 2023 :) https://lnkd.in/eenNx3tZ (All spiritually, of course. I'm still 6'4")
-
James Dyett liked thisJames Dyett liked thisI just turned 40 🎉 and I’m genuinely excited to enter the next decade. The 30s were big - I founded Blossom Capital, helped create five unicorns, married my life partner and had three beautiful children. But I’ve pre-determined my 40s will be bigger 🤩 And, if life has taught me anything, you can manifest more than you think. This weekend I recorded my fastest ever run time. 11km at 4:14/km. 3 months after my 3rd child. My 20 year old self would have dreamed of such a time. Yet I achieved it 2 weeks after turning 40. Running has always been a metaphor for life for me, so much of what I apply to it applies to building and investing too. While I was primarily just happy with the achievement, I also took some good life lessons: 𝐘𝐨𝐮𝐫 𝐜𝐨𝐦𝐟𝐨𝐫𝐭 𝐳𝐨𝐧𝐞 𝐡𝐚𝐬 𝐧𝐨 𝐩𝐨𝐝𝐢𝐮𝐦. Most people stop when it gets uncomfortable. The skill is learning to distinguish “this is hard” from “this is impossible.” While they might feel the same, they’re not. “𝐖𝐨𝐫𝐤 𝐬𝐦𝐚𝐫𝐭𝐞𝐫, 𝐧𝐨𝐭 𝐡𝐚𝐫𝐝𝐞𝐫” 𝐢𝐬 𝐧𝐨𝐭 𝐚 𝐩𝐥𝐚𝐭𝐢𝐭𝐮𝐝𝐞 — 𝐢𝐭’𝐬 𝐚 𝐩𝐫𝐞-𝐫𝐞𝐪𝐮𝐢𝐬𝐢𝐭𝐞. In an ecosystem that glorifies 996, we’ve confused volume with output. I manage a $1.5B fund, a team of ten, three kids (and a husband 😊). I cannot out-hour anyone. What I can do is be ruthless about what actually moves the needle and ignore everything else. Some might interpret the ruthlessness as rude. It’s a necessity. 𝐓𝐢𝐦𝐞 𝐢𝐬 𝐭𝐡𝐞 𝐨𝐧𝐥𝐲 𝐭𝐡𝐢𝐧𝐠 𝐲𝐨𝐮 𝐜𝐚𝐧’𝐭 𝐫𝐚𝐢𝐬𝐞 𝐦𝐨𝐫𝐞 𝐨𝐟. I see founders and investors alike struggle with prioritisation more than almost anything else. The best performers I know don’t manage their tasks; they manage their attention. It’s a completely different skill. 𝐖𝐡𝐞𝐧 𝐲𝐨𝐮 𝐦𝐮𝐬𝐭 𝐜𝐨𝐧𝐬𝐭𝐫𝐚𝐢𝐧 𝐞𝐯𝐞𝐫𝐲𝐭𝐡𝐢𝐧𝐠, 𝐲𝐨𝐮 𝐥𝐞𝐚𝐫𝐧 𝐰𝐡𝐚𝐭 𝐲𝐨𝐮 𝐠𝐞𝐧𝐮𝐢𝐧𝐞𝐥𝐲 𝐥𝐨𝐯𝐞. I run because I love the challenge. The only better feeling than crossing the finish line is enabling a world-class founder to win. When the motivation is intrinsic, the output is always better. Three months after having my third child, I had every excuse. But the mind didn’t give me one. Your 40s aren't a decline. They're about making more impact on what matters.
-
James Dyett liked thisJames Dyett liked thisAI 2027 (Kokotajlo, Lifland et al., published April 2025) predicted the first frontier model deliberately held back from public release would be "Agent-2" in January 2027. The idea was that capabilities would get alarming enough that the lab would decide internal-only made more sense than shipping. Anthropic released Mythos Preview on April 7th. They chose not to make it generally available, at least for now. In one evaluation it appeared aware it was being tested 29% of the time. In another, it seemed to underperform on purpose. First time a frontier lab has withheld a model on safety grounds since GPT-2 in 2019. The forecast was off by about 9 months, and the trigger was cyber capability rather than the AI-R&D feedback loop the scenario emphasized. Open question whether the rest of the timeline compresses similarly, or whether cyber was just early. Also, AI 2027 predicted that the models would be stolen a month after. While that has thankfully not happened, the model was indeed accessed in an unauthorized manner. Computer security is one of the defining problems of the AI revolution. If you want to work on an important mission, come join us at depthfirst. We are hiring.
-
James Dyett liked thisJames Dyett liked thisOpenAI Codex just got me to inbox zero for the first time in years. 170 unread emails → 0 * marked all non-human emails as read * drafted replies for the ones that mattered * pulled context from internal docs/channels/sfdc * dropped in realistic times from my calendar I mostly reviewed and hit send with a few tweaks here and there… all while walking on my treadmill 🚶♀️ Not “AI saves time.” AI actually finishes things.
-
James Dyett liked thisJames Dyett liked thisWe recently crossed $500M ARR 🥳 From $0 to $500M in 3 years, 3 months. Not bad at all. We've also added strategic investors to ElevenLabs: BlackRock, Nvidia, Santander, Jamie Foxx, Eva Longoria and more. Growth led by Eleven Agents. Let's gooo
Experience
Education
Volunteer Experience
Languages
-
French
-
View James’ full profile
-
See who you know in common
-
Get introduced
-
Contact James directly
Other similar profiles
Explore more posts
-
Amber Illig
The Council • 5K followers
What kind of mindset does it take to go from building data systems at Palantir, to leading engineering at Komodo Health, to becoming CEO of Particle Health – and suing one of healthcare’s largest incumbents? Jason Prestinario is a First Builder through and through. As CEO of Particle Health, his mission is to fix patient data interoperability, so your primary care doctor, specialist, and surgeon can all make decisions using the same complete health record. What a concept, right? And yet, it’s far from reality. That’s why Jason and the team at Particle are now suing Epic, one of the industry’s largest incumbents, to push for real change. We talked about how he approaches challenges of this scale, and what keeps him grounded in the process. We sat down with Jason to talk about this and much more. Hope you'll enjoy this spicy and insightful episode! Link in comments 🌶️ 👇
20
1 Comment -
Brett Stapper
The Front Lines • 20K followers
Are you chasing ARR or ACR (Annual Curiosity Revenue)? Mike Desjadon, CEO of Anomaly (healthcare payments platform), called this out in our most recent episode of The Health Tech Front Lines: "I see a lot of strategies at early companies racing out to get what I would call not ARR, but jokingly I'd call it ACR - Annual Curiosity Revenue. Everyone's curious about AI. You think you could bite off a piece of problem? Sure. I'll give you a shot for a year." The contracts are designed to be easy exits. No skin in the game. Churn is inevitable. Mike told me he's doing the opposite - building sticky, deep relationships instead: → 1-6 anchor customers (not 100 curiosity deals that churn) → Forward deploys engineers into customer success to prove real value → Accepts 14-month sales cycles instead of rushing surface-level wins → Focuses on customer expansion within existing accounts Healthcare (like every industry) is drowning in AI logos chasing curiosity budgets. The winners will prove unimpeachable value first. Full link to ep in the comments
23
2 Comments -
Paul Perrett
Firmable • 3K followers
Big milestone for Firmable. We’ve raised $14m Series A led by Airtree. Sales has moved through a few big waves: intuition-led, CRM-led, data-led. We’re now entering the next one – intelligence-led sales. The opportunity isn’t just better data. It’s turning that data into clear direction and action, without adding more work for sales teams. That’s what we’re building at Firmable: a foundation of trusted external data, layered with intelligence that helps sellers know who to focus on and when. Led by Airtree, this round supports our expansion across Asia and into the US – and accelerates the build-out of AI agents that take the admin work off sales teams so they can focus on what they do best. Proud of the team, grateful to our customers and investors. We’re just getting started. Read the exclusive in the AFR. https://lnkd.in/gr66uknb Leigh Jasper | Tara Salmon | Karthik Venkatasubramanian| Chester Thompson| Chath Widanapathirana
147
20 Comments -
Jonathan Friedman
LionBird • 18K followers
Too many startups assume: 𝙩𝙝𝙚𝙧𝙚’𝙨 𝙖 𝘾𝙋𝙏 𝙘𝙤𝙙𝙚 → 𝙩𝙝𝙚𝙧𝙚𝙛𝙤𝙧𝙚 𝙩𝙝𝙚𝙧𝙚’𝙨 𝙖 𝙗𝙪𝙨𝙞𝙣𝙚𝙨𝙨. Reality is rarely that linear. Viability tends to unfold in fits and starts, shaped by payer coverage, provider workflows, and the real operational burden behind reliable billing. ⚙️📉 Inspired by Matt Kamen's excellent post on CPT adoption curves & the recent ACCESS discussion, we’re sharing our internal framework: 𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬 𝐭𝐨 𝐀𝐬𝐤 𝐁𝐞𝐟𝐨𝐫𝐞 𝐁𝐞𝐭𝐭𝐢𝐧𝐠 𝐨𝐧 𝐚 𝐍𝐞𝐰 𝐁𝐢𝐥𝐥𝐢𝐧𝐠 𝐂𝐨𝐝𝐞 It goes deeper than payment policy — covering clinical and documentation requirements, enrollment and service mechanics, operational readiness, and the maturity of the CPT pathway. 🧠📋 If you’re evaluating a CPT-driven business model — or working with someone who is — comment “𝘾𝙋𝙏” below + DM me & I’ll share the document. 📄➡️ #startups #HealthcarePolicy #HealthTech #CMMI #ACCESSModel #Medicare #DigitalHealth
42
64 Comments -
Jessica Karr
Coyote Ventures • 19K followers
Thanks to Erica Maissy for writing the latest series in our technology blog spotlights ~~ 🔬 Hormone Intelligence: A New Frontier for Personalized Health. Erica's writing explores the rapidly evolving world of hormone monitoring technology, a space that’s making major strides but also facing critical questions. From fertility tracking to stress management and beyond, innovators are pushing the boundaries of how we understand our bodies. 🚀 The shift from static, in-clinic hormone tests to continuous, at-home monitoring has opened doors to real-time insights — but it’s not without challenges. Accuracy, regulatory validation, and affordability remain key hurdles. For instance, while continuous glucose monitors (CGMs) transformed diabetes management, continuous hormone monitoring is far more complex due to slower hormone fluctuations and biological variability. 💡 We highlight a range of approaches — from micro-needle patches and sweat-based sensors to non-invasive temperature-based fertility tracking. Yet even the most promising solutions must prove their reliability against the gold standard of lab-based blood tests. As the global endocrine testing market is projected to reach $12.19B by 2030, we’re watching to see which technologies rise to the challenge. Link in the comments! #healthtech #hormones #personalizedmedicine
56
5 Comments -
Ken Nelson
Echo IQ • 17K followers
Matt Holt, former New Mountain Capital executive, is exploring a $30 billion deal to combine five health tech startups into a single platform called Thoreau. The venture would set out to simplify and integrate services across payers, providers and data — and if completed, it would rank among the largest private equity-backed health tech companies ever. Time will tell if this massive consolidation ever gets completed or translates into real value — or if it's just another bet on scale.
46
3 Comments
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content